Bizaxofusp clinical trials
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 1999
How each study uses bizaxofusp is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 1999 (1)
| Year | Studies |
|---|---|
| 1999 | 1 |
| 2001 | 1 |
| 2002 | 1 |
| 2009 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 1
Neurocrine Biosciences (2) · Medicenna Therapeutics, Inc. (1) · Barrett Cancer Center (1) · Sophiris Bio Corp (1)
Studies
Open first, then newest update. How each study uses bizaxofusp is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive GlioblastomaCompletedPhase 2Medicenna Therapeutics, Inc.NCT02858895Written as MDNA55How we know
- IL-4(38-37)-PE38KDEL Immunotoxin in Treating Patients With Recurrent Malignant AstrocytomaStatus unknownPhase 1Barrett Cancer CenterNCT00003842Written as interleukin-4 PE38KDEL cytotoxinHow we know
- Intravenous Interleukin-4 PE38KDEL Cytotoxin in Treating Patients With Recurrent or Metastatic Kidney Cancer, Non-Small Cell Lung Cancer, or Breast CancerCompletedPhase 1Neurocrine BiosciencesNCT00039052Written as interleukin-4 PE38KDEL cytotoxinHow we know
- NBI-3001 Followed by Surgery in Treating Patients With Recurrent Glioblastoma MultiformeCompletedPhase 2Neurocrine BiosciencesNCT00014677Written as interleukin-4 PE38KDEL cytotoxinHow we know
- Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)WithdrawnPhase 2Sophiris Bio CorpNCT00797940Written as IL-4PEHow we know
Codes
What other systems call bizaxofusp · ClinicalTrials.gg INT004588
- UNII (FDA) FRY3MOL2QUBIZAXOFUSPOne source FDA
- NCI Thesaurus C79843BizaxofuspOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | FRY3MOL2QU | BIZAXOFUSP | One source FDA |
| NCI Thesaurus | C79843 | Bizaxofusp | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.